Lisata Therapeutics enters non-exclusive license agreement with Catalent
PositiveFinancial Markets

Lisata Therapeutics has entered into a non-exclusive license agreement with Catalent, marking a significant step in their collaboration. This partnership is expected to enhance Lisata's capabilities in drug development and manufacturing, which is crucial for bringing innovative therapies to market. Such agreements are vital in the pharmaceutical industry as they allow companies to leverage each other's strengths, ultimately benefiting patients with new treatment options.
— Curated by the World Pulse Now AI Editorial System